EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Urine-derived renal epithelial cells for deep phenotyping and transcriptomic response to therapy in Fabry disease

Praveen Dhondurao Sudhindar iD, Sarah E Orr iD, Eve Miller-Hodges iD, Elisa Molinari iD, Katrina Wood, Shalabh Srivastava iD, Colin G Miles, Holly R Mabillard iD, Zachary T Sentell iD, Marco Trevisan-Herraz, Juliana E Arcila-Galvis iD, John A Sayer iD

Clinical Science · 2025

DOI: 10.1042/cs20255570 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Clinical Science, 2025. Verfasst von Praveen Dhondurao Sudhindar und 11 weiteren Autor:innen. Beteiligte Einrichtung: Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Central Parkway, Newcastle upon Tyne, United Kingdo…. Hauptthemen laut MEDLINE: Fabry Disease, Epithelial Cells, Transcriptome, Kidney. Die Arbeit nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sanofi, Kidney Research UK, Northern Counties Kidney Research Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fabry disease is an X-linked lysosomal storage disorder caused by α-galactosidase A deficiency, leading to glycosphingolipid accumulation and progressive organ damage. Renal involvement is a major complication, yet diagnosis often requires an invasive kidney biopsy, and follow-up relies on indirect biomarkers or imaging, which lack specificity. Here, we present human urine-derived renal epithelial cells (hURECs) as a minimally invasive alternative for phenotyping renal Fabry disease and monitoring treatment response. Using hURECs from a newly diagnosed male Fabry disease patient, transmission electron microscopy (TEM) revealed lysosomal inclusions consistent with native kidney biopsy findings. Bulk RNA sequencing (RNA-seq) identified a transcriptomic disease signature, including dysregulated pathways involved in lipid metabolism homeostasis, ion transport, endoplasmic reticulum stress response, and collagen processing. Following systemic treatment of the patient with chaperone therapy, partial amelioration of the hUREC transcriptomic signature was observed during the first few months. However, by nine months, the signature began reverting toward baseline, correlating with continued kidney function decline. This prompted a transition to enzyme replacement therapy, with early evaluations showing transcriptomic stabilization. Our findings demonstrate that hURECs replicate key structural and molecular markers of renal Fabry disease and offer a non-invasive platform for longitudinal assessment of treatment response. TEM of hURECs provides a diagnostic alternative to biopsy, while RNA-seq-based transcriptomic profiling offers a sensitive and dynamic view of molecular changes, including key dysregulated pathways. This dual utility positions hURECs as a novel tool for improving the diagnosis, monitoring, and personalized management of kidney involvement in Fabry disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fabry DiseaseEpithelial CellsTranscriptomeKidneyUrineHumansMaleEnzyme Replacement TherapyPhenotypealpha-GalactosidaseGene Expression Profiling

Stichwörter der Autor:innen

Fabry diseaseRNA-seqchaperoneelectron microscopyenzyme replacement therapyurine-derived renal epithelial cells

Substanzen

alpha-Galactosidase

Autor:innen und Institutionen

  • Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Central Parkway, Newcastle upon Tyne, United Kingdom.
  • Centre for Cardiovascular Science, Queen's Medical Research Institute, University of Edinburgh, Edinburgh, United Kingdom.
  • Department of Cellular Pathology, Royal Victoria Infirmary Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom.
  • Sunderland Royal Infirmary, Sunderland, United Kingdom.
  • Biosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom.
  • Renal Services, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom.

ORCID-Profile: Praveen Dhondurao Sudhindar, Sarah E Orr, Eve Miller-Hodges, Elisa Molinari, Shalabh Srivastava, Holly R Mabillard, Zachary T Sentell, Juliana E Arcila-Galvis, John A Sayer

Förderung

  • Sanofi
  • Kidney Research UK
  • Northern Counties Kidney Research Fund
  • Medical Research Council
  • LifeArc

Zitieren

APA

Sudhindar, P. D., Orr, S. E., Miller-Hodges, E., Molinari, E., Wood, K., Srivastava, S., Miles, C. G., Mabillard, H. R., Sentell, Z. T., Trevisan-Herraz, M., Arcila-Galvis, J. E., & Sayer, J. A. (2025). Urine-derived renal epithelial cells for deep phenotyping and transcriptomic response to therapy in Fabry disease. Clinical Science. https://doi.org/10.1042/cs20255570

Vancouver

Sudhindar PD, Orr SE, Miller-Hodges E, Molinari E, Wood K, Srivastava S, et al. Urine-derived renal epithelial cells for deep phenotyping and transcriptomic response to therapy in Fabry disease. Clinical Science. 2025. doi:10.1042/cs20255570

BibTeX
@article{Sudhindar2025,
  author = {Sudhindar, Praveen Dhondurao and Orr, Sarah E and Miller-Hodges, Eve and Molinari, Elisa and Wood, Katrina and Srivastava, Shalabh and Miles, Colin G and Mabillard, Holly R and Sentell, Zachary T and Trevisan-Herraz, Marco and Arcila-Galvis, Juliana E and Sayer, John A},
  title = {Urine-derived renal epithelial cells for deep phenotyping and transcriptomic response to therapy in Fabry disease},
  journal = {Clinical Science},
  year = {2025},
  doi = {10.1042/cs20255570}
}
Kostenlos starten →